photo pending
Growth hormone-releasing peptide-2 (GHRP-2), also known as pralmorelin, is a synthetic hexapeptide investigated primarily as an agonist of the GH secretagogue receptor type 1a (GHS-R1a). Although much of the scientific literature focuses on growth hormone (GH) signaling, experimental studies have also measured changes in other pituitary-associated hormones, including prolactin (PRL).
The endocrine selectivity of GHRP-2 can be better understood thanks to these observations. Experimental evidence suggests that its signaling can be accompanied by quantifiable responses in a number of other neuroendocrine systems, rather than functioning only within GH-associated pathways.
Why Is Prolactin Measured in GHRP-2 Research?
Prolactin is measured in GHRP-2 research to help researchers assess the compound’s endocrine selectivity and determine whether its experimental effects extend beyond its principal growth hormone-associated signalling pathway.
When investigating a receptor agonist, researchers often measure several biochemical or hormonal markers rather than examining a single endpoint. This helps determine how selective the experimental compound is for its principal signaling pathway.
GHRP-2 primarily interacts with GHS-R1a, a G-protein-coupled receptor associated with the endogenous ligand ghrelin. GHS-R1a signaling has been studied extensively in pituitary and hypothalamic systems.
Researchers have investigated whether prolactin, adrenocorticotropic hormone (ACTH), and cortisol responses are associated with experimental GHRP-2 exposure because these systems are involved in larger neuroendocrine signaling networks.
Does GHRP-2 Affect Prolactin in Experimental Studies?
Small increases in prolactin after exposure to GHRP-2 under particular study settings have been documented in published experimental research.
Published experimental research has reported small increases in prolactin following GHRP-2 exposure under specific study conditions.
A frequently cited study by Arvat and colleagues compared GHRP-2 and hexarelin with other endocrine stimuli. Both synthetic growth hormone-releasing peptides elicited strong GH responses but smaller prolactin responses. The researchers described GHRP-2 and hexarelin as not being completely specific for GH secretion because measurable responses in PRL, ACTH, and cortisol were observed.
Importantly, the magnitude of the prolactin response was lower than that produced by thyrotropin-releasing hormone (TRH) in the same experimental investigation.
This distinction matters. The study demonstrates that prolactin can be included among the biochemical variables associated with experimental GHRP-2 research, but it does not establish prolactin as the compound's primary signaling endpoint.
GHRP-2 Is Not Completely Selective for GH-Associated Responses
The prolactin findings are part of a broader observation regarding GHRP-2's endocrine selectivity.
In addition to prolactin, controlled investigations have measured ACTH and cortisol responses following experimental GHRP-2 exposure. Arvat et al. reported measurable ACTH and cortisol responses alongside the substantially larger GH response.
Other research has subsequently investigated GHRP-2 specifically as an experimental probe of the hypothalamic-pituitary-adrenal signaling system. These studies provide additional evidence that the biochemical response to GHRP-2 is not limited to somatotroph-associated GH signaling.
Why Might GHRP-2 Produce Multiple Endocrine Responses?
GHS-R1a operates within a complex neuroendocrine signaling network rather than as an isolated receptor system.
The receptor is a class A G protein-coupled receptor and the recognized receptor for ghrelin. Research into GHS-R1a has identified complex downstream signaling properties, including substantial ligand-independent or constitutive activity.
Additionally, GHS-R1a participates in signaling outside of the pituitary GH system and is expressed in a variety of organs. As a result, research on GHRP-2 can shed light on both its specific GH-secretagogue activity and the more general metabolic reactions linked to ghrelin receptor activation.
The observation of prolactin, ACTH, and cortisol responses therefore provides researchers with additional markers for characterizing the selectivity and neuroendocrine pharmacology of GHRP-2.
GHRP-2 Prolactin Research Summary
Prolactin is not the primary endocrine endpoint of GHRP-2; however, it has elicited quantifiable prolactin responses in controlled experimental settings, according to the available data.
The available findings are more appropriately interpreted as evidence concerning the peptide's endocrine selectivity rather than evidence for any particular physiological or health outcome.
In laboratory research, prolactin can therefore be considered one of several biochemical markers used to characterize the broader neuroendocrine response associated with experimental GHRP-2 exposure.
GHRP-2 and Prolactin Frequently Asked Questions
GHRP-2 is primarily characterized as an agonist of GHS-R1a rather than the prolactin receptor. Experimental prolactin responses are therefore investigated within the wider neuroendocrine response associated with GHRP-2 signaling.
No. Growth hormone has historically been the principal endocrine marker examined in GHRP-2 research. Prolactin is one of several additional markers measured to assess the compound's endocrine selectivity.
In addition to prolactin, experimental studies have examined GH, ACTH, and cortisol. Researchers can compare responses from various pituitary and neuroendocrine pathways with the use of these data.
In the Arvat et al. investigation, GHRP-2 produced a strong GH response while its prolactin-stimulating activity was comparatively smaller. The findings support classifying GH secretion as a principal experimental response to GHRP-2.
Measuring multiple endocrine markers allows researchers to determine whether the biochemical response to a compound is confined to its principal pathway of investigation. For GHRP-2, measurements of PRL, ACTH, and cortisol demonstrate that the experimental responses are not entirely restricted to GH-associated signaling.
GHRP-2 is primarily investigated as an agonist of GH secretagogue receptor type 1a (GHS-R1a), also known as the ghrelin receptor. GHS-R1a is a G-protein-coupled receptor involved in a complex network of intracellular and neuroendocrine signaling.
Scientific references
- 1 Arvat E, Di Vito L, Maccagno B, et al. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides. 1997;18(6):885–891. doi:10.1016/S0196-9781(97)00016-8. https://pubmed.ncbi.nlm.nih.gov/9285939/
- 2 Laviano A, Molfino A, Rianda S, Rossi Fanelli F. The growth hormone secretagogue receptor (Ghs-R). Curr Pharm Des. 2012;18(31):4749–4754. doi:10.2174/138161212803216906. https://pubmed.ncbi.nlm.nih.gov/22632856/
- 3 Davenport AP, Bonner TI, Foord SM, et al. International Union of Pharmacology. LVI. Ghrelin receptor nomenclature, distribution, and function. Pharmacol Rev. 2005;57(4):541–546. https://pubmed.ncbi.nlm.nih.gov/16382107/
- 4 Kimura T, Shimatsu A, Arimura H, et al. Concordant and discordant ACTH responses induced by GHRP-2, CRH and insulin-induced hypoglycemia in patients with hypothalamopituitary disorders. Endocr J. 2010. doi:10.1507/endocrj.K10E-017. https://pubmed.ncbi.nlm.nih.gov/20431231/
- 5 Kageyama K, et al. Investigation of the clinical significance of the growth hormone-releasing peptide-2 test for the diagnosis of secondary adrenal failure. Endocr J. 2016. doi:10.1507/endocrj.EJ15-0587. https://pubmed.ncbi.nlm.nih.gov/27020037/
Research-use disclaimer: For research and laboratory use only. Not for human or animal consumption.